Filing Flows › GeneDx Holdings (WGS) › Next earnings date
GeneDx Holdings (WGS) earnings on Nov 9, 2026: what to expect
GeneDx Holdings (WGS) is expected to report earnings on Nov 9, 2026, tomorrow, for the quarter ending Sep 30, 2026. Analysts expect EPS of $0.07 ($0.07 to $0.08, 7 estimates) on revenue of $123M, against $0.49 and $117M a year ago. It beat the EPS estimate in 75% of the quarters on record; Filing Flows' model gives it a 76% chance of beating next time.
What to watch
Last quarter (Q2 2026) the lines that make up revenue grew like this; the report shows whether the trend holds:
Filing Flows' own estimate from the SEC figures — the same quarter last year times recent growth — is EPS $0.26 on revenue of $137M, against the analysts' $0.07.
The last report
GeneDx Holdings reported revenue of $114M for the second quarter 2026 (+11% Y/Y), net loss $17.7M: Diagnostic Test $112M, Other revenue $2.6M. How it makes money → · Every quarter →
GeneDx Holdings' latest quarter
GeneDx Holdings, Q2 2026: revenue $114M (+11% year over year), operating margin -15.3%, net loss $17.7M, operating cash flow −$29.0M. The chart follows the revenue to costs, profit and cash.
Questions
When does WGS report earnings?
GeneDx Holdings is expected to report on Nov 9, 2026.
What are analysts expecting from GeneDx Holdings?
EPS of $0.07 and revenue of $123M for the quarter.
Does GeneDx Holdings usually beat earnings?
It beat the consensus EPS estimate in 75% of the quarters on record.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.